Submit Manuscript  

Article Details


Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer

[ Vol. 13 , Issue. 5 ]

Author(s):

Feng Li, Tengfei Zhang, Ling Cao and Yi Zhang*   Pages 327 - 335 ( 9 )

Abstract:


Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.

Keywords:

Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.

Affiliation:

Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan



Read Full-Text article